FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933494280> ?p ?o ?g. }

• W2933494280 endingPage "e0214332" @default.
• W2933494280 startingPage "e0214332" @default.
• W2933494280 abstract "Focal and Segmental Glomerulosclerosis (FSGS) is a severe glomerulopathy that frequently leads to end stage renal disease. Only a subset of patients responds to current therapies, making it important to identify alternative therapeutic options. The interleukin (IL)-1 receptor antagonist anakinra is beneficial in several diseases with renal involvement. Here, we evaluated the potential of anakinra for FSGS treatment. Molecular process models obtained from scientific literature data were used to build FSGS pathology and anakinra mechanism of action models by exploiting information on protein interactions. These molecular models were compared by statistical interference analysis and expert based molecular signature matching. Experimental validation was performed in Adriamycin- and lipopolysaccharide (LPS)-induced nephropathy mouse models. Interference analysis (containing 225 protein coding genes and 8 molecular process segments) of the FSGS molecular pathophysiology model with the drug mechanism of action of anakinra identified a statistically significant overlap with 43 shared molecular features that were enriched in pathways relevant in FSGS, such as plasminogen activating cascade, inflammation and apoptosis. Expert adjudication of molecular signature matching, focusing on molecular process segments did not suggest a high therapeutic potential of anakinra in FSGS. In line with this, experimental validation did not result in altered proteinuria or significant changes in expression of the FSGS-relevant genes COL1A1 and NPHS1. In summary, an integrated bioinformatic and experimental workflow showed that FSGS relevant molecular processes can be significantly affected by anakinra beyond the direct drug target IL-1 receptor type 1 (IL1R1) context but might not counteract central pathophysiology processes in FSGS. Anakinra is therefore not suggested for extended preclinical trials." @default.
• W2933494280 created "2019-04-11" @default.
• W2933494280 creator A5001061320 @default.
• W2933494280 creator A5011003633 @default.
• W2933494280 creator A5028317069 @default.
• W2933494280 creator A5049043084 @default.
• W2933494280 creator A5055746341 @default.
• W2933494280 creator A5063039551 @default.
• W2933494280 creator A5068919447 @default.
• W2933494280 date "2019-03-28" @default.
• W2933494280 modified "2023-10-14" @default.
• W2933494280 title "A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis" @default.
• W2933494280 cites W1549139000 @default.
• W2933494280 cites W1785643923 @default.
• W2933494280 cites W1966595061 @default.
• W2933494280 cites W1975752601 @default.
• W2933494280 cites W1978627153 @default.
• W2933494280 cites W2003286878 @default.
• W2933494280 cites W2006902949 @default.
• W2933494280 cites W2009132304 @default.
• W2933494280 cites W2036834425 @default.
• W2933494280 cites W2040670636 @default.
• W2933494280 cites W2049628599 @default.
• W2933494280 cites W2057158494 @default.
• W2933494280 cites W2065079609 @default.
• W2933494280 cites W2072802709 @default.
• W2933494280 cites W2087325419 @default.
• W2933494280 cites W2106132002 @default.
• W2933494280 cites W2133272865 @default.
• W2933494280 cites W2136850043 @default.
• W2933494280 cites W2142840454 @default.
• W2933494280 cites W2142895007 @default.
• W2933494280 cites W2155540606 @default.
• W2933494280 cites W2180891493 @default.
• W2933494280 cites W2232176000 @default.
• W2933494280 cites W2334736175 @default.
• W2933494280 cites W2337907746 @default.
• W2933494280 cites W2432114750 @default.
• W2933494280 cites W2465781320 @default.
• W2933494280 cites W2571522407 @default.
• W2933494280 cites W2593771998 @default.
• W2933494280 cites W2618084763 @default.
• W2933494280 cites W2735271739 @default.
• W2933494280 cites W2753521545 @default.
• W2933494280 cites W2763597778 @default.
• W2933494280 cites W2776864848 @default.
• W2933494280 cites W2796168841 @default.
• W2933494280 cites W2811143061 @default.
• W2933494280 cites W2826750344 @default.
• W2933494280 cites W95902050 @default.
• W2933494280 doi "https://doi.org/10.1371/journal.pone.0214332" @default.
• W2933494280 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6438574" @default.
• W2933494280 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30921378" @default.
• W2933494280 hasPublicationYear "2019" @default.
• W2933494280 type Work @default.
• W2933494280 sameAs 2933494280 @default.
• W2933494280 citedByCount "8" @default.
• W2933494280 countsByYear W29334942802020 @default.
• W2933494280 countsByYear W29334942802021 @default.
• W2933494280 countsByYear W29334942802023 @default.
• W2933494280 crossrefType "journal-article" @default.
• W2933494280 hasAuthorship W2933494280A5001061320 @default.
• W2933494280 hasAuthorship W2933494280A5011003633 @default.
• W2933494280 hasAuthorship W2933494280A5028317069 @default.
• W2933494280 hasAuthorship W2933494280A5049043084 @default.
• W2933494280 hasAuthorship W2933494280A5055746341 @default.
• W2933494280 hasAuthorship W2933494280A5063039551 @default.
• W2933494280 hasAuthorship W2933494280A5068919447 @default.
• W2933494280 hasBestOaLocation W29334942801 @default.
• W2933494280 hasConcept C126322002 @default.
• W2933494280 hasConcept C2777390665 @default.
• W2933494280 hasConcept C2778415529 @default.
• W2933494280 hasConcept C2779134260 @default.
• W2933494280 hasConcept C2779561371 @default.
• W2933494280 hasConcept C2780091579 @default.
• W2933494280 hasConcept C2781228260 @default.
• W2933494280 hasConcept C60644358 @default.
• W2933494280 hasConcept C71924100 @default.
• W2933494280 hasConcept C86803240 @default.
• W2933494280 hasConcept C98274493 @default.
• W2933494280 hasConceptScore W2933494280C126322002 @default.
• W2933494280 hasConceptScore W2933494280C2777390665 @default.
• W2933494280 hasConceptScore W2933494280C2778415529 @default.
• W2933494280 hasConceptScore W2933494280C2779134260 @default.
• W2933494280 hasConceptScore W2933494280C2779561371 @default.
• W2933494280 hasConceptScore W2933494280C2780091579 @default.
• W2933494280 hasConceptScore W2933494280C2781228260 @default.
• W2933494280 hasConceptScore W2933494280C60644358 @default.
• W2933494280 hasConceptScore W2933494280C71924100 @default.
• W2933494280 hasConceptScore W2933494280C86803240 @default.
• W2933494280 hasConceptScore W2933494280C98274493 @default.
• W2933494280 hasFunder F4320321181 @default.
• W2933494280 hasFunder F4320323591 @default.
• W2933494280 hasIssue "3" @default.
• W2933494280 hasLocation W29334942801 @default.
• W2933494280 hasLocation W29334942802 @default.
• W2933494280 hasLocation W29334942803 @default.
• W2933494280 hasLocation W29334942804 @default.

• next